Schedule of enrolment, interventions and assessments
| Study period | |||
| Enrolment | Postallocation | Close-out | |
| Timepoints | Month 0 | Month 3 | Month 6 |
| Eligibility screen | X | – | – |
| Informed consent | X | – | – |
| Allocation | X | – | – |
| Delivery of the experimental product | X | – | – |
| Delivery of a participating card | X | – | – |
| Instructions to keep and return the pillboxes | X | – | – |
| Interventions | |||
| Oral resveratrol | |||
| Oral placebo | |||
| Assessments | |||
| Baseline variables | |||
| Demographics | X | – | – |
| Medical history | X | – | – |
| Outcome measures (analyses planned) | |||
| Knee pain | X | X | X |
| WOMAC function subscore | X | X | X |
| Patient global assessment | X | X | X |
| OARSI–OMERACT response | – | X | X |
| Analgesics and NSAIDs consumption | X | X | X |
| Injections of hyaluronic acid and/or corticosteroids | X | X | X |
| Collected variables (no analyses planned) | |||
| Symptomatic slow acting drugs for OA consumption | |||
| Non-pharmacological co-interventions | X | X | X |
| Adverse events | – | X | X |
| Adherence | – | X | X |
NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; OARSI, Osteoarthritis Research Society International; OMERACT, Outcome Measures in Rheumatology; WOMAC, Western Ontario and McMaster Universities Arthritis Index.